BMY

58.8000.79%
AL

Adam Lenkowsky

Executive VP & Chief Commercialization Officer

Mr. Adam Lenkowsky serves as its Executive Vice President and Chief Commercialization Officer at Bristol-Myers Squibb Company since April 26, 2023 and served as its Head of U.S. Oncology. Mr. Lenkowsky serves as a Director at Capital Health System, Inc. since 2020. Mr. Adam Lenkowsky is the general manager and head of U.S. Cardiovascular, Immunology and Oncology at Bristol Myers Squibb (BMS). He leads an organization of more than 2,500 employees that deliver transformational medicines such as Eliquis, Opdivo, Yervoy and Orencia. Mr. Adam is an experienced leader who has held numerous senior strategic and operational roles across the company. In his most recent role, he headed BMS’ U.S. Oncology business, which, by revenue produced, was the single largest therapeutic division with BMS during his tenure. In 2014, he led the Worldwide Oncology Commercialization team. In this role, he oversaw the launch of Opdivo, is widely recognized as one of the most successfully launched oncology products in history. Mr. Adam was instrumental in the design and creation of BMS’ Integrated Oncology operating model to drive speed and success for its marketed and pipeline oncology assets. Mr. Adam’s full biopharma career extends many years across commercial, market access, sales and operations. He has held a number of commercial leadership positions at BMS. He earned his bachelor’s degree in biology from the State University of New York at Albany.

Positions